Drug Profile
Research programme: immunomodulatory drugs - Celgene
Alternative Names: CC-0478765; CC-0478995; CC-13097; CC-15965Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Phthalimides; Piperidones; Small molecules
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 07 May 2007 This programme is still in active development in the USA